Semaglutide showed efficacy and safety in overweight/obese patients with CKD, supporting its use in this high-risk population with significant unmet need.
Key findingSemaglutide showed efficacy and safety in overweight/obese patients with CKD, supporting its use in
What the researchers found
Semaglutide showed efficacy and safety in overweight/obese patients with CKD, supporting its use in this high-risk population with significant unmet need.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Semaglutide 2.4 mg weekly. Inclusion: eGFR ≥25, UACR ≥30, BMI ≥27. Primary endpoint: percentage change in UACR.
How the study worked
In publication.
Who was studied
Adults with CKD (eGFR ≥25, UACR ≥30), BMI ≥27, without diabetes
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.
Nature medicine, 31(1), 278-285
Citation
Apperloo, Ellen M; Gorriz, Jose L; Soler, Maria Jose; Cigarrán Guldris, Secundino; Cruzado, Josep M; Puchades, Maria Jesús; López-Martínez, Marina; Waanders, Femke; Laverman, Gozewijn D; van der Aart-van der Beek, Annemarie; Hoogenberg, Klaas; van Beek, André P; Verhave, Jacobien; Ahmed, Sofia B; Schmieder, Roland E; Wanner, Christoph; Cherney, David Z I; Jongs, Niels; Heerspink, Hiddo J L. (2025). Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.. Nature medicine, 31(1), 278-285. https://doi.org/10.1038/s41591-024-03327-6